CD28-B7

Definition

CD28-B7 is a critical co-stimulatory signaling pathway essential for T cell activation and survival during the adaptive immune response. CD28, a receptor found on T cells, interacts with B7 molecules (B7-1/CD80 and B7-2/CD86) expressed on antigen-presenting cells (APCs). This interaction provides necessary secondary signals that promote T cell proliferation, cytokine production, and long-term immunity, bridging the innate and adaptive immune systems.

5 Must Know Facts For Your Next Test

1. The CD28-B7 interaction is crucial for the activation of naive T cells upon their first encounter with an antigen.
2. Blocking CD28 signaling can lead to an impaired immune response, making it a target for therapies in autoimmune diseases and cancer immunotherapy.
3. CD28 is constitutively expressed on T cells, while B7 molecules are upregulated on APCs during infection or inflammation.
4. The interaction between CD28 and B7 also plays a role in promoting T cell survival by enhancing anti-apoptotic signaling pathways.
5. In addition to CD28, other receptors like CTLA-4 and PD-1 can bind to B7 molecules, providing a regulatory mechanism to prevent overactivation of T cells.

Review Questions

• How does the CD28-B7 interaction enhance T cell activation compared to TCR signaling alone?
  • The CD28-B7 interaction provides essential co-stimulatory signals that amplify the activation process initiated by T cell receptor (TCR) signaling. While TCR recognizes specific antigens presented by MHC molecules, CD28 engagement with B7 molecules on antigen-presenting cells delivers secondary signals that promote full T cell activation. This synergistic action leads to increased proliferation, cytokine production, and the generation of memory T cells, ensuring a robust adaptive immune response.
• Discuss the implications of targeting the CD28-B7 pathway in immunotherapy for cancer treatment.
  • Targeting the CD28-B7 pathway in cancer immunotherapy holds significant potential due to its role in enhancing T cell activation and function. By stimulating this pathway, therapies can boost the immune system's ability to recognize and attack tumor cells. However, careful modulation is required because excessive activation can lead to autoimmunity. Therefore, balancing co-stimulation through CD28 while controlling negative regulatory signals from other receptors like CTLA-4 is crucial for effective cancer treatment.
• Evaluate how the dysregulation of the CD28-B7 pathway can contribute to autoimmune diseases.
  • Dysregulation of the CD28-B7 pathway can lead to an inappropriate or excessive T cell activation, which is a hallmark of autoimmune diseases. If the co-stimulatory signals from CD28 are unchecked or overly activated due to factors like increased expression of B7 molecules on APCs, it may result in T cells attacking self-antigens. This disruption creates a scenario where self-tolerance is lost, contributing to conditions such as rheumatoid arthritis or lupus. Understanding this dysregulation helps in developing targeted therapies aimed at restoring balance in the immune response.

Related terms

T Cell Receptor (TCR): A molecule on the surface of T cells that recognizes specific antigens presented by major histocompatibility complex (MHC) molecules.

Antigen-Presenting Cell (APC): A type of immune cell, such as dendritic cells or macrophages, that processes and presents antigens to T cells to initiate an immune response.

Cytokines:

Small signaling proteins released by cells that mediate and regulate immunity, inflammation, and hematopoiesis.